SCHEMBL20554192

SCHEMBL20554192

N=C(N)c1ccc(F)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UBE2T Q9NPD8 2/20 0.49
LMNA P02545 2/20 0.43
PLAU P00749 2/20 0.43
MASP2 O00187 1/20 0.43
THPO P40225 1/20 0.43
PRSS1 P07477 6/20 0.42
F2 P00734 3/20 0.41
APEX1 P27695 1/20 0.41
PRSS3 P35030 1/20 0.41
ST14 Q9Y5Y6 1/20 0.40
PRMT5 O14744 1/20 0.40
PRMT1 Q99873 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
CYP2C19 P33261 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TMPRSS2 O15393 1/20 0.39
F10 P00742 1/20 0.39
F12 P00748 1/20 0.39
F7 P08709 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2514244 0.78 NNMT (0.61) F7F3
SCHEMBL30074590 0.78 NNMT (0.61) F7F3
SCHEMBL28344110 0.77 P4HA1 (0.52) UBE2TLMNAPLAUMASP2THPO
Hydrochloric Acid SCHEMBL5009748 0.77 NNMT (0.59) F7F3
SCHEMBL14993008 0.75 GAA (0.40) LMNAHSD17B10
SCHEMBL14993009 0.75 KCNQ3 (0.38) CYP2C19
SCHEMBL14993007 0.75 GAA (0.40) LMNAHSD17B10
SCHEMBL8324617 0.74 UBE2T (0.54) UBE2TLMNAPLAUMASP2THPO
SCHEMBL15149909 0.74 UBE2T (0.49) UBE2TLMNAPLAUMASP2THPO
SCHEMBL2514243 0.74 KCNQ3 (0.44) ALDH1A1HPGDCYP2C19HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4023640-A1 PHENYLIMIDAZOLE COMPOUND Otsuka Pharmaceutical Factory, Inc. (JP) 2022-07-06 EP disclosed
CN-113200962-A Phenylimidazole compounds 株式会社大塚制药工场 2021-08-03 CN disclosed
CN-108430977-B Phenylimidazole compounds 株式会社大塚制药工场 2021-06-08 CN disclosed
US-10570117-B2 Phenylimidazole compound OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2020-02-25 US disclosed
US-20180354930-A1 PHENYLIMIDAZOLE COMPOUND OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2018-12-13 US disclosed
EP-3401310-A1 PHENYLIMIDAZOLE COMPOUND Otsuka Pharmaceutical Factory, Inc. (JP) 2018-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10570117-B2 Phenylimidazole compound LPL, PNLIP, LIPC UBE2T 3500/4885LMNA 1063/4885PLAU 504/4885
US-20180354930-A1 PHENYLIMIDAZOLE COMPOUND PNLIP, PLIN1, HDAC11 UBE2T 3367/4885LMNA 3128/4885PLAU 2663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.